Efficacy and Safety of Pulse Magnetic Therapy System in Insomnia Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial
3
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective This study’s objective is to assess the efficacy and safety of Pulsed Magnetic Therapy System (PMTS) in improving insomnia disorder.Methods Participants with insomnia disorder were randomly assigned to receive either PMTS or sham treatment for four weeks (n= 153; PMTS: 76, sham: 77). Primary outcomes are the Insomnia Severity Index (ISI) scores at week 0 (baseline), 1, 2, 3, 4 (treatment), and 5 (follow-up). Secondary outcomes are the Pittsburgh Sleep Quality Index at baseline and week 4, and weekly sleep diary-derived values for sleep latency, sleep efficiency, real sleep time, waking after sleep onset, and sleep duration.Results The ISI scores of the PMTS group and the sham group were 7.13±0.50, 11.07±0.51 at week 4, respectively. There was a significant group×time interaction for ISI (F3.214, 485.271=24.25, p<0.001, ηp 2=0.138). Only the PMTS group experienced continuous improvement throughout the study; in contrast, the sham group only experienced a modest improvement after the first week of therapy. At the end of the treatment and one week after it, the response of the PMTS group were 69.7% (95% confidence interval [CI]: 58.6%–79.0%), 75.0% (95% CI: 64.1%–83.4%), respectively, which were higher than the response of the sham group (p<0.001). For each of the secondary outcomes, similar group×time interactions were discovered. The effects of the treatment persisted for at least a week.Conclusion PMTS is safe and effective in improving insomnia disorders.
Abstract
Objective This study’s objective is to assess the efficacy and safety of Pulsed Magnetic Therapy System (PMTS) in improving insomnia disorder.Methods Participants with insomnia disorder were randomly assigned to receive either PMTS or sham treatment for four weeks (n= 153; PMTS: 76, sham: 77). Primary outcomes are the Insomnia Severity Index (ISI) scores at week 0 (baseline), 1, 2, 3, 4 (treatment), and 5 (follow-up). Secondary outcomes are the Pittsburgh Sleep Quality Index at baseline and week 4, and weekly sleep diary-derived values for sleep latency, sleep efficiency, real sleep time, waking after sleep onset, and sleep duration.Results The ISI scores of the PMTS group and the sham group were 7.13±0.50, 11.07±0.51 at week 4, respectively. There was a significant group×time interaction for ISI (F3.214, 485.271=24.25, p<0.001, ηp 2=0.138). Only the PMTS group experienced continuous improvement throughout the study; in contrast, the sham group only experienced a modest improvement after the first week of therapy. At the end of the treatment and one week after it, the response of the PMTS group were 69.7% (95% confidence interval [CI]: 58.6%–79.0%), 75.0% (95% CI: 64.1%–83.4%), respectively, which were higher than the response of the sham group (p<0.001). For each of the secondary outcomes, similar group×time interactions were discovered. The effects of the treatment persisted for at least a week.Conclusion PMTS is safe and effective in improving insomnia disorders.
참고문헌 (30)
- Perlis ML, "Insomnia", Lancet, 400, pp.1047~1060 (2022)
- Zhang J, "A communitybased study of insomnia in Hong Kong Chinese children : prevalence, risk factors and familial aggregation", Sleep Med, 10, pp.1040~1046 (2009)
- Morin CM, "Insomnia disorder", Nat Rev Dis Primers, 1, pp.15026~ (2015)
- Kay-Stacey M, "Advances in the management of chronic insomnia", BMJ, 354, pp.i2123~ (2016)
- Lane JM, "Biological and clinical insights from genetics of insomnia symptoms", Nat Genet, 51, pp.387~393 (2019)
- Buysse DJ, "Insomnia", JAMA, 309, pp.706~716 (2013)
- Wickwire EM, "Health economics of insomnia treatments : the return on investment for a good night’s sleep", Sleep Med Rev, 30, pp.72~82 (2016)
- Morin CM, "Chronic insomnia", Lancet, 379, pp.1129~1141 (2012)
- Harvey AG, "Cognitive behaviour therapy for primary insomnia : can we rest yet?", Sleep Med Rev, 7, pp.237~262 (2003)
- Strauch B, "Evidence-based use of pulsed electromagnetic field therapy in clinical plastic surgery", Aesthet Surg J, 29, pp.135~143 (2009)
- Wang T, "Pulsed electromagnetic fields : promising treatment for osteoporosis", Osteoporos Int, 30, pp.267~276 (2019)
- Vadalà M, "Mechanisms and therapeutic applications of electromagnetic therapy in Parkinson’s disease", Behav Brain Funct, 11, pp.26~ (2015)
- Arendash GW, "Electromagnetic treatment to old Alzheimer’s mice reverses β-amyloid deposition, modifies cerebral blood flow, and provides selected cognitive benefit", PLoS One, 7, pp.e35751~ (2012)
- Vadalà M, "Mechanisms and therapeutic effectiveness of pulsed electromagnetic field therapy in oncology", Cancer Med, 5, pp.3128~3139 (2016)
- Hattapoğlu E, "Efficiency of pulsed electromagnetic fields on pain, disability, anxiety, depression, and quality of life in patients with cervical disc herniation : a randomized controlled study", Turk J Med Sci, 49, pp.1095~1101 (2019)
- Lefaucheur JP, "Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation(rTMS) : an update(2014-2018)", Clin Neurophysiol, 131, pp.474~528 (2020)
- Riemann D, "The hyperarousal model of insomnia : a review of the concept and its evidence", Sleep Med Rev, 14, pp.19~31 (2010)
- Van Someren EJW, "Brain mechanisms of insomnia : new perspectives on causes and consequences", Physiol Rev, 101, pp.995~1046 (2021)
- Gramowski-Voß A, "Enhancement of cortical network activity in vitro and promotion of GABAergic neurogenesis by stimulation with an electromagnetic field with a 150 MHz carrier wave pulsed with an alternating 10 and 16 Hz modulation", Front Neurol, 6, pp.158~ (2015)
- Feng J, "The effect of sequential bilateral low-frequency rTMS over dorsolateral prefrontal cortex on serum level of BDNF and GABA in patients with primary insomnia", Brain Behav, 9, pp.e01206~ (2019)
- Jiang B, "Efficacy and placebo response of repetitive transcranial magnetic stimulation for primary insomnia", Sleep Med, 63, pp.9~13 (2019)
- Jiang B, "Efficacy and placebo response of multimodal treatments for primary insomnia : a network meta-analysis", Clin Neuropharmacol, 42, pp.197~202 (2019)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- Morin CM, "The insomnia severity index : psychometric indicators to detect insomnia cases and evaluate treatment response", Sleep, 34, pp.601~608 (2011)
- Chung KF, "Assessing insomnia in adolescents : comparison of Insomnia Severity Index, Athens Insomnia Scale and Sleep Quality Index", Sleep Med, 12, pp.463~470 (2011)
- Bushnell MC, "Cognitive and emotional control of pain and its disruption in chronic pain", Nat Rev Neurosci, 14, pp.502~511 (2013)
- Riemann D, "Sleep, insomnia, and depression", Neuropsychopharmacology, 45, pp.74~89 (2020)
- Herrero Babiloni A, "The effects of non-invasive brain stimulation on sleep disturbances among different neurological and neuropsychiatric conditions : a systematic review", Sleep Med Rev, 55, pp.101381~ (2021)
- Zewdie E, "Safety and tolerability of transcranial magnetic and direct current stimulation in children : prospective single center evidence from 3. 5 million stimulations", Brain Stimul, 13, pp.565~575 (2020)
- Vgontzas AN, "Insomnia with objective short sleep duration : the most biologically severe phenotype of the disorder", Sleep Med Rev, 17, pp.241~254 (2013)